Fig. 5.

Univariate sensitivity analysis of the differences in total annual health plan costs per PASI 75 among patients a with prior biologic failure and b without prior biologic failure and treated with ustekinumab vs. brodalumab. PASI Psoriasis Area Severity Index. PASI 75 efficacy rates were varied between the ranges of their respective 95% confidence intervals; incremental cost estimates were varied ± 30%. Non-responder medical cost: average annual total medical costs associated with PASI < 75. AE adverse event